KEYLearning Hub

Optimise the care of your M/uR HNSCC patients

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) [External links]

Welcome to the KEYLearning Hub in HNSCC, a peer-to-peer learning hub created with Oncologists to host an array of educational resources on the pathway, management and care of patients with metastatic or unresectable recurrent HNSCC with KEYTRUDA® (pembrolizumab).

Patient case studies

Choosing KEYTRUDA in M/uR HNSCC with CPS 1-19

Dr Caroline Brammer
First published on MSD Connect: September 2023

Treatment pathway

PD-L1 testing and the head and neck cancer pathway

Dr Christina Wilson
Published on MSD Connect: March 2022


HNSCC = Head And Neck Squamous Cell Carcinoma; M/uR = Metastatic Or Unresectable Recurrent.

Supporting documentation

Prescribing Information (Great Britain) & Prescribing Information (Northern Ireland) 
By clicking the links above you will leave the MSD Connect website and be taken to the emc PI portal website